Longeveron Management
Management criteria checks 0/4
Longeveron's CEO is Mohamed Wa'el Hashad, appointed in Feb 2023, has a tenure of 2.25 years. total yearly compensation is $1.85M, comprised of 30.9% salary and 69.1% bonuses, including company stock and options. directly owns 0.96% of the company’s shares, worth $194.47K. The average tenure of the management team and the board of directors is 1.8 years and 1.9 years respectively.
Key information
Mohamed Wa'el Hashad
Chief executive officer
US$1.8m
Total compensation
| CEO salary percentage | 30.88% |
| CEO tenure | 2.3yrs |
| CEO ownership | 1.0% |
| Management average tenure | 1.8yrs |
| Board average tenure | 1.9yrs |
Recent management updates
Recent updates
ELPIS II And Alzheimer Programs Will Accelerate FDA Approval
Successful trial enrollment and regulatory designations could accelerate Longeveron's market entry and future revenue growth through streamlined FDA pathways and partnerships.Is Longeveron (NASDAQ:LGVN) In A Good Position To Invest In Growth?
Mar 05
Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely?
Nov 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$26m |
| Dec 31 2024 | US$2m | US$571k | -US$25m |
| Sep 30 2024 | n/a | n/a | -US$27m |
| Jun 30 2024 | n/a | n/a | -US$28m |
| Mar 31 2024 | n/a | n/a | -US$22m |
| Dec 31 2023 | US$2m | US$431k | -US$22m |
Compensation vs Market: Mohamed Wa'el's total compensation ($USD1.85M) is above average for companies of similar size in the US market ($USD651.56K).
Compensation vs Earnings: Mohamed Wa'el's compensation has increased whilst the company is unprofitable.
CEO
Mohamed Wa'el Hashad (62 yo)
Mr. Mohamed Wa'el Ahmed Hashad, M.B.A. has been Chief Executive Officer at Longeveron Inc. since February 2023 and also has been its Director since June 09, 2023. Mr. Hashad had been Independent Director a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.3yrs | US$640.39k | 7.94% $ 1.6m | |
| CEO & Director | 2.3yrs | US$1.85m | 0.96% $ 194.5k | |
| CFO, Executive VP & Treasurer | 1.8yrs | US$1.12m | 0.39% $ 78.3k | |
| General Counsel & Secretary | no data | US$1.23m | 0.88% $ 176.8k | |
| CTO & Senior VP of Chemistry | less than a year | no data | 0.085% $ 17.2k | |
| Chief Medical Officer | 1.8yrs | no data | 0.38% $ 77.6k | |
| Vice President of Manufacturing | no data | no data | no data | |
| VP of Research & Discovery | no data | no data | no data | |
| VP & Corporate Controller | less than a year | no data | no data |
Experienced Management: LGVN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.3yrs | US$640.39k | 7.94% $ 1.6m | |
| CEO & Director | 1.9yrs | US$1.85m | 0.96% $ 194.5k | |
| Independent Director | less than a year | US$56.26k | 0.027% $ 5.4k | |
| Independent Director | 1yr | US$60.23k | 0.036% $ 7.2k | |
| Independent Director | less than a year | US$56.13k | 0.027% $ 5.4k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.9yrs | US$120.31k | 0.084% $ 17.0k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | 5.2yrs | US$101.56k | 1.52% $ 305.8k | |
| Independent Director | 3.9yrs | US$113.81k | 0.12% $ 25.0k |
Experienced Board: LGVN's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/27 00:50 |
| End of Day Share Price | 2025/05/27 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Longeveron Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Boobalan Pachaiyappan | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |